72 results
DEFA14A
AUPH
Aurinia Pharmaceuticals Inc
3 Jun 24
Additional proxy soliciting materials
6:28pm
this Plan; “Award Commitment” means any written agreement, contract or other instrument or document evidencing any Award granted under this Plan. Each Award … Commitment shall be subject to the applicable terms and conditions of this Plan and any other terms and conditions (not inconsistent with this Plan
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
demonstrates our full commitment to solid execution and driving growth, as we continue in our work of delivering LUPKYNIS to patients in need.”
Earlier
8-K
EX-99.1
e1bpq5 r1f8ohcl
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-99.1
v2bkk0
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
EX-10.1
22ig 1lj2xno22z
21 Sep 23
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
4:06pm
S-8
msqmepwg vmo0
26 May 23
Registration of securities for employees
4:39pm
S-8
EX-10.1
3h018d1ag8ih uazo
25 Jun 21
Registration of securities for employees
4:31pm
8-K
EX-99.1
naww4sj5j5egpj1vevqs
10 Jun 21
Departure of Directors or Certain Officers
4:08pm
DEF 14A
pqhcpgglj ij
10 May 21
Definitive proxy
4:06pm
PRE 14A
aeulsps7
27 Apr 21
Preliminary proxy
4:32pm
S-8
EX-5.1
c8n7 avbj0di0um
24 Feb 21
Registration of securities for employees
4:28pm